-
公开(公告)号：UY31114A1
公开(公告)日：2009-01-05
申请号：UY31114
申请日：2008-05-30
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor： EBERT ULRICH , JUAN VERONICA M , HINTON PAUL R , LABKOVSKY BORIS , STRIEBINGER ANDREAS R , KELLER PATRICK , HILLEN HEINZ , BARGHORN STEFAN
Abstract: Proteínas de unión, y en particular, anticuerpos humanizados que pueden usarse, por ejemplo, en el diagnóstico, el tratamiento y la prevención de la enfermedad de Alzheimer y condiciones relacionadas.
-
公开(公告)号：AU2008260062A1
公开(公告)日：2008-12-11
申请号：AU2008260062
申请日：2008-05-30
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor： EBERT ULRICH , LABKOVSKY BORIS , HINTON PAUL R , BARGHORN STEFAN , KELLER PATRICK , HILLEN HEINZ , STRIEBINGER ANDREAS R , JUAN VERONICA M
Abstract: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
-
公开(公告)号：CA2671217A1
公开(公告)日：2008-06-05
申请号：CA2671217
申请日：2007-11-29
Applicant: ABBOTT LAB , ABBOTT GMBH & CO KG
Inventor： KELLER PATRICK , EBERT ULRICH , LABKOVSKY BORIS , STRIEBINGER ANDREAS R , HILLEN HEINZ , BARGHORN STEFAN
IPC: A61K39/395 , A61K31/711 , C12N15/09
Abstract: The subject invention relates to monoclonal antibodies that may be used i n the treatment and diagnosis of Alzheimer's Disease. In particular, the pre sent invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
-
公开(公告)号：AU2006319358A1
公开(公告)日：2007-06-07
申请号：AU2006319358
申请日：2006-11-30
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor： BARGHORN STEFAN , KELLER PATRICK , LABKOVSKY BORIS , HILLEN HEINZ , STRIEBINGER ANDREAS , EBERT ULRICH
Abstract: Anti-A² globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A² globulomer antibodies having a binding affinity to A²(20-42) globulomer that is greater than the binding affinity of the antibody to A²(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
-
公开(公告)号：CA2805859A1
公开(公告)日：2005-05-26
申请号：CA2805859
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
Patent Agency Ranking
公开(公告)号：AU2004290073A1
公开(公告)日：2005-05-26
申请号：AU2004290073
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： JIA XIAO-CHI , WIELER JAMES , GREEN LARRY , HEDBERG BRAD , LABKOVSKY BORIS , BABCOOK JOHN , KANG JASPAL SINGH , VOSS JEFFREY W , GHAYUR TARIQ
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：SK284040B6
公开(公告)日：2004-08-03
申请号：SK106298
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor 'alpha' (hTNF'alpha') are disclosed. These antibodies have high affinity for hTNF'alpha'(e.g., Kd = 10exp(-8) M or less), a slow off rate for hTNF'alpha' dissociation (e.g., Koff = 10exp(-3) sec-1 or less) and neutralize hTNF'alpha' activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF'alpha' and for inhibiting hTNF'alpha' activity, e.g., in a human subject suffering from a disorder in which hTNF'alpha' activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：HU0300423A2
公开(公告)日：2003-06-28
申请号：HU0300423
申请日：2001-02-09
Applicant: ABBOTT LAB
Inventor： BROCKLEHURST SIMON MARK , DIXON RICHARD W , DUNCAN ALEXANDER ROBERT , GHAYUR TARIQ , LABKOVSKY BORIS , LENNARD SIMON NICHOLAS , MANKOVICH JOHN , ROGUSKA MIKE , SALFELD JOCHEN , SHORROCK CELIA PATRICIA , THOMPSON JULIA ELIZABETH , WHITE MICHAEL
IPC: A61K39/395 , C12N15/02 , A61K45/00 , A61P1/04 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/02 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：SK12942002A3
公开(公告)日：2003-05-02
申请号：SK12942002
申请日：2001-02-09
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , DIXON RICHARD W , ROGUSKA MIKE , WHITE MICHAEL , LABKOVSKY BORIS , SALFELD JOCHEN , DUNCAN ALEXANDER ROBERT , BROCKLEHURST SIMON MARK , MANKOVICH JOHN , SHORROCK CELIA PATRICIA , THOMPSON JULIA ELIZABETH , LENNARD SIMON NICHOLAS
IPC: A61K39/395 , C12N15/02 , A61K45/00 , A61P1/04 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/02 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , C07K16/00
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：CA2800450A1
公开(公告)日：2001-08-16
申请号：CA2800450
申请日：2001-02-09
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , DIXON RICHARD W , ROGUSKA MIKE , WHITE MICHAEL , LABKOVSKY BORIS , SALFELD JOCHEN , DUNCAN ALEXANDER ROBERT , BROCKLEHURST SIMON MARK , MANKOVICH JOHN , SHORROCK CELIA PATRICIA , THOMPSON JULIA ELIZABETH , LENNARD SIMON NICHOLAS
IPC: C07K16/24 , C12N15/02 , A61K39/395 , A61K45/00 , A61P1/04 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/02 , C07K1/22 , C07K14/54 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/08 , C40B30/04
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.023 seconds)
